EuroTEST and HepHIV 2026 Dublin Conference, 2-3 November 2026

Venue: Radisson Blue Royal Hotel, Dublin

Overall objectives:

- Keeping testing and linkage to care on policy and implementation agendas at European and national level
- Discuss synergies between HIV, viral hepatitis, TB and STIs as well as other health priorities (i.e. cancer prevention)

Monday, 2 November 2026			
Registration opens at 12			
Time (GMT)	**Room: Field Suite**	**Room: Green Room**	
11:00-13:00	**From Guidance to Practice: Implementing BBV Opt-Out Testing in European Emergency Departments (open meeting)**	**SHIELD Joint Action Working Group (closed meeting)**	
	Advisory and stakeholder roundtable discussion on implementation of BBV opt-out testing in Emergency Departments		
13:15-14:45	**Strengthening research capacity in Eastern Europe through the WEEPI foundation (open meeting)**		
	Explore how WEEPI, a unique researcher-led research foundation, advances research excellence, scientific collaboration and evidence-based healthcare solutions in Eastern Europe. The meeting will include examples from researchers leading WEEPI-supported projects and guidance on manuscript writing.		
Time (GMT)	**Room: Goldsmith 1+2**		**Moderators & speakers**
15:00-15:55	**OS**	**OPENING SESSION** • **Session objectives:** Progress toward the Sustainable Development Goals and other global targets, including challenges ahead and priorities for maintaining HIV, viral hepatitis, STIs and TB on the political agenda. • Continued efforts to reduce Inequalities in access to testing for infectious diseases	**Moderators:** **Stephen O´Hare, HepHIV2026 Conference Co-chair, HIV Ireland, Ireland** **Jürgen Rockstroh, HepHIV2026 Conference Co-chair, University of Bonn, Germany**
15:00-15:10	OS/01	Welcome to the HepHIV 2026 Dublin Conference	Conference co-chairs
15:10-15:20	OS/02	Welcome message from the Minister of Health of Ireland	**Minister of Health Jennifer Carroll MacNeil**, Department of Health, Ireland
15:20-15:25	OS/03	Keynote from the European Commission	**EU Commissioner for Health and Animal Welfare Olivér Várhelyi**, European Commission (by video)
15:25-15:30	OS/04	Keynote from the European Centre for Disease Prevention and Control, ECDC	**Director Pamela Rendi-Wagner**, European Centre for Disease Prevention and Control, ECDC (by video)
15:30-15:35	OS/05	Keynote from the WHO Regional Office for Europe	**Officer-In-Charge and Director, Programme Management Corinne Capuano**, WHO Regional Office for Europe (by video)
15:35-15:45	OS/06	Community perspective	**Executive Director Stephen O´Hare**, HIV Ireland, Ireland

15:45-15:55	OS/07	A clinical perspective from Ireland	**Professor Eoin Feeney,** Consultant in Infectious Diseases, St Vincent's University Hospital, Dublin and Professor in Infectious Diseases at UCD School of Medicine, Ireland
15:55-16:25	**Coffee break**		
Time (GMT)	**Room: Goldsmith 1+2**		**Moderators & speakers**
16:25-18:00	**PL1**	**PLENARY SESSION 1: Zooming in on testing for infectious diseases, progress and remaining challenges in reaching the SDGs** **Session objectives:** Status of reaching SDG targets and identifying gaps in implementation of testing programmes in Europe, discuss obstacles to linkage to care from testing services	**Moderators:** **Stela Bivol, WHO Regional Office for Europe** **Jens Lundgren, CHIP, Rigshospitalet, University of Copenhagen, Denmark**
16:25-16:40	PL1/01	Status on HIV, hepatitis, STIs and TB testing in Europe	**Teymur Noori**, European Centre for Disease Prevention and Control, ECDC
16:40-16:55	PL1/02	Implementation of testing guidelines and understanding coverage of testing at country levels	**Victor Daniel Miron**, Carol Davila University of Medicine and Pharmacy Bucharest, Romania
16:55-17:10	PL1/03	The role of community leadership in integrated testing services and ensuring high rates of linkage to care	**Mariana Vicente**, GAT - Grupo de Ativistas em Tratamentos, Portugal **Laura Fernàndez-López,** Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Spain
17:10-17:25	PL1/04	Integrated testing in migrant populations – inclusion in other health services and linkage to care considerations	**Lisa George-Svahn**, Noaks Ark Stockholm, Region Stockholm healthcare services, Karolinska Institute, Sweden
17:25-17:40	PL1/05	Network-based HIV case finding and linkage to care in Ukraine	**Pavlo Smyrnov,** Alliance for Public Health (APH), Ukraine
17:40-18:00		Discussion	
18:00-19:00	**Poster Session and Poster Walks**		
19:00-21:00	**Reception**		

Tuesday, 3 November 2026

Time (GMT)	**Room: Goldsmith 1+2**		**Room: Goldsmith 3**	
8:30-9:30	**AS1**	**PARALLEL SESSION 1:** **Integrated testing in health care settings, including emergency departments** **Moderators: Johanna Brännström, South Hospital & Institute of Medicine, Karolinska Institute, Sweden & Carlos Mejia-Chew, St. Vincent's University Hospital, University College Dublin, Ireland**	**AS2**	**PARALLEL SESSION 2:** **Integrated testing and linkage to care in community settings** **Moderators: Ben Collins, ReShape/International HIV Partnerships (IHP), United Kingdom & Nikos Dedes, Positive Voice, Greece**

8:30-8:40	AS1/01	**Bloodborne virus testing in Danish emergency departments: a national baseline study** D. Podlekareva, Centre of Excellence for Health, Immunity and Infections (CHIP), Copenhagen University Hospital – Rigshospitalet, Denmark	AS2/01	**Sexy Side of the Netherlands: An Alternative Approach to Engage MSM and Transgender Newcomers in STI/HIV Testing and Care** T Mouhebati, Soa Aids Nederland, the Netherlands
8:40-8:50	AS1/02	**Data for Action: Health and economic impact of emergency department blood-borne virus opt-out testing in high-burden urban centres in Belgium, Greece, and Poland** L. Bates, Aquarius Population Health, United Kingdom and A. Libois, Saint-Pierre University Hospital Brussels, Belgium	AS2/02	**Impact of European Testing Week on HIV, HCV and Syphilis Testing in Community-Based Services: A COBATEST Network Analysis** L. Fernandez, Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Spain
8:50-9:00	AS1/03	**Integrated HIV, Viral Hepatitis and Tuberculosis Infection Testing Across Multiple Healthcare Settings in Lithuania** S. Raudonis, Vilnius University, Faculty of Medicine, Lithuania	AS2/03	**HIV diagnosis and linkage-to-care outcomes within community-led integrated HIV, HCV, HBV and syphilis testing services in the Lisbon Metropolitan Area, Portugal (2021–2025)** F. Gomes, GAT - Grupo de Ativistas em Tratamentos, Portugal
9:00-9:10	AS1/04	**TARGET-ID: Algorithm risk-based targeted identification and testing of people at risk of HIV, hepatitis B and hepatitis C in primary care: a feasibility study** W. Leber, Queen Mary University of London, United Kingdom	AS2/04	**Psychoactive Substance Use and HIV and HCV Screening Test Outcomes Among Clients of Voluntary Counselling and Testing (VCT) Points in Poland, 2022–2025** A. Szczepański, Jagiellonian University Medical College, Poland
9:10-9:20	AS1/05	**Hospital-based HCV screening as a first step towards integrated blood-borne virus testing in Italy: A national delphi consensus study** L.A. Kondili, Istituto Superiore di Sanità, Italy	AS2/05	**Linkage to care for hepatitis B infection among migrant populations screened in Portugal: preliminary data from the VH-COMSAVAC project** F Cota Medeiros, Faculty of Medicine, University of Lisbon, Portugal
9:20-9:30		**Discussion**		**Discussion**

09:30-10:00	**Coffee Break and Poster Session**		
Time (GMT)	**Room: Goldsmith 1+2**		**Moderators & speakers**
10:00-11:10	**PL2**	**PLENARY SESSION 2: Optimising offer of testing for HIV, viral hepatitis, STIs and TB in medical settings – lessons learned and challenges ahead** **Session objectives:** • Discuss the potential of testing in health care settings • Understand the obstacles of consent requirements and requirements for medical personnel across Europe	**Moderators:** **Ann Sullivan, Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom** **Jessica Hicks, World Hepatitis Alliance, United Kingdom**
10:00-10:25		**PLENARY SESSION 2 – Part 1**	
10:00-10:15	PL2/01	Launching the implementation guidance on BBV testing in emergency departments	**Michael Rayment,** Chelsea & Westminster Hospital, United Kingdom **Emma Young,** Barts Health NHS Trust, United Kingdom
10:15-10:25	PL2/02	Linkage to care considerations from testing in emergency departments - a community perspective	**Garry Brough,** United Kingdom
10:25-11:10		**PLENARY SESSION 2 – Part 2**	
10:25-11:10		**Roundtable discussion** Consent requirements and lay provider testing – what is the status in Europe and what can we learn	**Jürgen Rockstroh,** University of Bonn, Germany **Garry Brough,** United Kingdom

			Konstantinos Protopapas, Attikon University Hospital of Athens, Greece **Loreta Kondili**, European Association for the Study of the Liver (EASL), Italy **Raimonda Matulionyte**, Vilnius University Hospital Santaros Klinikos, Vilnius University, Lithuania **Teymur Noori,** European Centre for Disease Prevention and Control, ECDC
11:10-11:15	**Short break**		
Time (GMT)	**Room: Goldsmith 1+2**		**Moderators & speakers**
11:15-12:45	**PL3**	**PLENARY SESSION 3: Creating an enabling environment for testing and linkage to care for HIV, viral hepatitis, STIs and TB** **Session objectives:** • Stigma interventions after stigma surveys • Discuss how lessons learned from HIV can be used to inform the implementation of diagnostic, preventive, and therapeutic interventions for other infections.	**Moderators:** **Teymur Noori, European Centre for Disease Prevention and Control, ECDC** **Denis Onyango, Africa Advocacy Foundation, United Kingdom**
11:15-11:30	PL3/01	Measuring stigma interventions in health care and other settings – where are we at?	**Julia del Amo,** Ministry of Health, Spain
11:30-11:45	PL3/02	Intervention Mapping as a tool for addressing HIV stigma: Insights from the RESET intervention in the Netherlands	**Sarah Stutterheim,** Maarstricht University, The Netherlands
11:45-12:00	PL3/03	Cultural competent practices that improve screening, diagnosis, and linkage to care	**Lucia Siracusa,** ARNAS Civico-Di Cristina, Italy
12:00-12:15	PL3/04	Employment of peer support and reaching outside service system	**Al Story,** University College London Hospitals, United Kingdom
12:15-12:30	PL3/05	ECDC/WHA hepatitis stigma survey - lessons learned and next steps	**Alexandra Smith**, World Hepatitis Alliance, United Kingdom
12:30-12:45		Discussion	
12:45-13:40	**Lunch break**		

Time (GMT)	**Room: Goldsmith 1+2**		**Room: Goldsmith 3**	
13:40-14:30	**AS3**	**PARALLEL SESSION 3:** **Policy implications and addressing structural barriers to implementation** **Moderators: Maria Prins, GGD Amsterdam, The Netherlands & Tom Platteau, Institute of Tropical Medicine, Belgium**	**AS4**	**PARALLEL SESSION 4:** **Focus on vulnerable populations and specific settings for interventions** **Moderators: Amanita Calderón-Cifuentes, Transgender Europe, TGEU, Germany & Sara Croxford, National Health Service (NHS), United Kingdom**
13:40-13:50	AS3/01	**Effectiveness of an online home-based self-sampling platform for HIV/STI testing in Belgium: results from the Test2Know pilot** T. Platteau, Institute of Tropical Medicine, Belgium	AS4/01	**More HIV Diagnoses During Event-Driven PrEP compared to Daily PrEP in the Netherlands** I. J.M. Willemstein, Public Health Service Amsterdam, The Netherlands

13:50-14:00	AS3/02	**From single-virus elimination to integrated testing: qualitative implementation learning from England's Viral Hepatitis Elimination Programme** A. Noonan and M. Gillyon-Powell, Viral Hepatitis Elimination Programme, Specialised Commissioning, NHS England, Unted Kingdom	AS4/02	**Experiences of stigma and discrimination among people who inject drugs in England, Wales and Northern Ireland** S. Croxford, UK Health Security Agency, United Kingdom
14:00-14:10	AS3/03	**Cost-effectiveness of emergency department opt-out testing for blood-borne viruses in England** J. Walker, University of Bristol, United Kingdom	AS4/03	**Gaps in HBV, HCV and HPV prevention, testing and care in European prisons: findings from 17 facilities in seven countries** R. Fuertes, University of Pisa, Italy
14:10-14:20	AS3/04	**Using participatory knowledge translation to develop an integrated HIV, STI and hepatitis B and C strategic framework for Belgium** J. Deblonde, Sciensano - Belgium Public Health Institute, Belgium	AS4/04	**Reaching the Unreached: Peer-Led Mobile HIV Testing and Outreach to Migrant and Asylum-Seeking Communities at Risk of Undiagnosed HIV and Treatment Interruption in Ireland** A. Piercy, HIV Ireland, Ireland
14:20-14:30		**Discussion**		**Discussion**
14:30-14:35	**Short break**			

Time (GMT)	**Room: Goldsmith 1+2**		**Moderators & speakers**
14:35-15:30	**CS**	**CLOSING SESSION** **Session objectives:** • Summarise the outcomes of the conference and present a draft call for action • Present and discuss opportunities to keep testing and linkage to care on policy and implementation agendas at European and national levels • Characterise sustainable testing strategies in the context of emergencies and getting closer to the targets	**Moderators:** **Michel Kazatchkine, Senior Advisor to WHO, Switzerland** **Jane O'Halloran, University College Dublin, School of Medicine, Ireland**
14:35-14:45	CS/01	Strengthening parliamentary leadership toward the Sustainable Development Goals and other global targets related to testing and linkage to care for HIV, viral hepatitis, STIs, and TB	**Lynn Ruane,** UNITE Parliamentarians Network for Global Health, Ireland
14:45-15:55	CS/02	Focus on the Eastern European Region	**Stela Bivol,** WHO Regional Office for Europe
14:55-15:05	CS/03	Focus on the Eastern European Region - innovative solutions and remaining challenges	**Tetiana Deshko,** Alliance for Public Health, Ukraine
15:05-15:20	CS/04	Opportunities for integrated efforts across disease areas	**Kevin Fenton,** Regional Director of Public Health, NHS London. Chief Advisor on HIV to Government, United Kingdom
15:20-15:30	CS/05	Best Poster Award, Conference Call to Action and closing remarks	HepHIV CO-chairs
17:00-18:00	**EuroTEST Steering Committee Meeting (Closed meeting)**		

Wednesday, 4 November 2026

09:00-14:00	**"Five Years, One Goal" Expert's group annual in-person meeting (Closed meeting)**

Poster walks will take place Monday, 2 November from 18:00-19:00:
Five posters will be selected by two poster moderators. Each selected poster presenter has 3 minutes to present and 2 minutes for questions.

Poster walk group 1: Moderators Daria Podlekareva and Maria Prins
Poster walk group 2: Moderators Magda Ankiersztejn-Bartczak and Ferenc Bagyinszky
Poster walk group 3: Moderators Stela Bivol and Michel Kazatchkine

Poster Category 1: Integrated testing in health care settings, including emergency departments

PO1/01	Opt-Out HIV Testing at Croydon's Emergency Department plays a crucial role in patient safety and reduction in HIV transmission: New diagnoses 2020 to 2024	I Cormack, Croydon University Hospital, United Kingdom
PO1/04	Adherence to antiretroviral therapy as an HIV prevention priority in the context of late diagnosis in Latvia	T A Fernandes, Riga Stradiņš University, Institute of Public Health, Latvia

Poster Category 2: Integrated testing and linkage to care in community settings

PO2/02	Optimizing the national HIVR response: the critical cole of Belgian CBOs in testing key populations	H Vermandere, Sciensano, Belgium
PO2/03	HIV and STI screening activity at Apoyo Positivo CASA community-based testing centres during 2025	J F Cabrera Solano, Apoyo Positivo, Spain
PO2/04	Bridging the Gap in Integrated HIV, Syphilis, Hepatitis B and C Testing: Overcoming Accessibility Barriers through Community-Led Strategies in Malmö, Sweden	A Ajomale, Noaks Ark Mosaik, Sweden
PO2/05	Community-based HIV and hepatitis C testing among MSM and vulnerable groups in Estonia, 2023–2025	M Kasianczuk, Estonian Network of PLWH (EHPV), Estonia
PO2/06	Bringing screening closer to those most at risk: hepatitis and HIV testing through the “Test in the City” project	P Meli, Don Giuseppe Monticelli Società Cooperativa Sociale, Italy
PO2/09	Collect2Know: an innovative low-cost device to facilitate fingerprick macro-capillary blood self-collection for HIV/STI testing	T Platteau, Institute Of Tropical Medicine, Belgium
PO2/10	TB/HIV Intersectional Stigma and Its Impact on Tuberculosis Infection Management in Central and Eastern Europe: A Scoping Review	Z Szulc, Master of Public Health Programme, Faculty of

		Medicine, Lund University, Sweden
PO2/11	Ten-Year Trends in Community-Based HIV, HBV, HCV, and Syphilis Testing and Reactivity in Portugal, 2016-2025	M J Novais, EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Universidade do Poro, Portugal
PO2/14	Promoting PrEP among people with a migration background in Belgium: experience of Plateforme's community PrEP campaign	T G Kouadio, La Plateforme, Belgium
Poster Category 3: Policy implications and addressing structural barriers to implementation		
PO3/01	Off-track for 2030: structural inequalities in oral HIV pre-exposure prophylaxis (PrEP) access across 27 European countries, 2022–2026	F Bagyinszky, AIDS Action Europe, Germany
PO3/04	Beyond Diversity: How a Multi-Stakeholder Network Advances the Right to Health	I Mercurio, Don Giuseppe Monticelli Società Cooperativa Sociale, Italy
PO3/05	HCV reinfection after cure among people receiving opioid agonist therapy in Ukraine: a 13-clinic cluster trial of onsite simplified care under different provider payment models	M Filippovych, Ukrainian Institute on Public Health Policy, Ukraine
PO3/06	ITSready project: Development and early implementation of an integrated digital ecosystem for STI/HIV self-sampling, partner notification and AI-supported sexual health information for teenagers and young adults	C Agustí, CEEISCAT-Agència de Salut Pública de Catalunya, Spain
PO3/07	Policy Responses to Expand Access to Viral Hepatitis Testing and Care in Ukraine During Wartime	I Skrypka, State Institution "Public Health Center of the Ministry of Health of Ukraine", Ukraine
PO3/08	A public health evaluation of an antenatal hepatitis C opt-out testing pilot in England	T Djuretic, UKHSA, United Kingdom
PO3/09	Finding the lost-to-follow-up: A Peer-Led Data Linkage and Case-Finding Model to Support Hepatitis C Elimination	A Story, UCLH Find&Treat, United Kingdom

PO3/10	From Oral PrEP to Long-Acting Formulations: The Evolution of Ukraine's National HIV Prevention Programme	I Mameletzis & L Krishchenko, World Health Organization Ukraine Country Office, Ukraine
PO3/11	Feasibility and Potential for Implementing Index HIV Self-Testing in Ukraine (pilot research)	A Kryshchuk, State institution Public Health Center of the Ministry of Health of Ukraine, Ukraine
PO3/12	Designing and delivering workshops using hepatitis C surveillance data and local intelligence to drive public health action and support regional progress to elimination goals in England	V Morris & N Sims, UK Health Security Agency, United Kingdom
PO3/13	From Research to Advocacy: Developing a Multilingual Media Content to Support TB Infection Screening in People with HIV in Central and Eastern Europe	G Pawłowska, Bachelor of Management and Sociology, Department of Management, Kozminski University, Warsaw
PO3/14	Seeing Beyond the Diagnosis: Using Visual Storytelling to Challenge HIV and Viral Hepatitis Stigma Through the PLHIV Documentary	S Doyle, PLHIV Documentary, Ireland
Poster Category 4: Focus on vulnerable populations and specific settings for interventions		
PO4/01	Mobile Outreach for Viral Hepatitis Micro-Elimination in Croatian Prisons: Improving Access to Diagnostics and Linkage to Care (2023–2025)	T Reic, Croatian Society for the Liver Diseases "Hepatos", Croatia
PO4/02	Implementing Community-Led Integrated HIV, HCV and Syphilis Testing in Polish Prisons: Experience from Foundation for Social Education	M Ankiersztejn-Bartczak, Foundation for Social Education, Poland
PO4/03	Nine Years of Integrated Community-Based Testing within a Harm Reduction Programme for People Who Inject Drugs by Foundation for Social Education in Warsaw, Poland	M Ankiersztejn-Bartczak, Foundation for Social Education, Poland
PO4/04	Efficacy of an Online HIV/STI Screening Addressed to Men Who Have Sex with Men Users of PrEP in Spain (TESTATE PrEP)	C Agustí, CEEISCAT-Agència de Salut Pública de Catalunya, Spain

PO4/05	HIV Self-Testing in Ukraine: Scaling Differentiated Testing Models Among Key Populations (2025)	S Vynohradova, Public Health Center of the MOH of Ukrain, Ukraine
PO4/06	Integrated biobehavioural survey among people who inject drugs (PWID) in Ukraine, 2023	M Moshura, Public Health Center of the MOH of Ukrain, Ukraine
PO4/07	Optimizing HIV, HBV and HCV screening via online self-sampling among GBMSM and trans people in Spain: The Pan-TESTATE project	C Agustí, CEEISCAT-Agència de Salut Pública de Catalunya, Spain
PO4/08	Women and HIV PrEP in Ukraine: Expanding Access Beyond Traditional Key Populations	O Klymova, State Institution "Public Health Center of the Ministry of Health of Ukraine", Ukraine
PO4/09	Integrating HIV, Hepatitis, and STI Services into Mental Health Care amidst Wartime Challenges: Lessons from Ukraine	V Virchenko, Taras Shevchenko National University of Kyiv, Ukraine
PO4/10	Four Years of STI Screening in a Portuguese University: Prevalence, Trends and Public Health Implications	A M Matos, LACUC - Clinical Laboratory Analysis from University of Coimbra, Portugal
PO4/11	Hepatitis B knowledge and self-reported testing and vaccination history among populations with increased risk in Georgia	L Gulbiani, Health Research Union, Georgia
PO4/12	The paradox of high coverage: persistent HCV reinfection in care-engaged MSM networks	D Calzavara, Prisma, Belgium
PO4/14	Considerations for implementing pharmacist testing programs for HIV and Hepatitis C – Analysis from two Canadian studies in community pharmacy and rural corrections sites	D V Kelly, Memorial University of Newfoundland & Labrador, Canada
PO4/15	Crosslink: Building on Lessons Learned to Improve Access to HIV/STI Services for Mobile and Migrant Population	T Mouhebati, Soa Aids Nederland, the Netherlands

PO4/16	HIV self-testing among people who inject drugs during the war in Ukraine: sustained coverage through NGO-led community-based prevention programs, 2023–2025	L Legkostup, Public Health Center of the MOH of Ukraine, Ukraine
PO4/17	A European prison sentinel network for viral hepatitis, HPV and harm reduction: structure and baseline feasibility in the PACE project	V Casigliani, University of Pisa, Italy
PO4/18	Formative Research of a Mobile Drug Consumption Room in Brno: Addressing Public Injecting and HCV Risks in a Socially Excluded Location	B Janikova, First Faculty of Medicine, Charles University, Czech Republic
PO4/19	Starting Opioid Agonist Therapy (OAT) But Missing the Test: Opportunities to Improve Hepatitis C Screening in Newfoundland and Labrador, Canada	C Balsom, Memorial University, Canada
PO4/20	Breaking Barriers in the Czech Republic: A Unique NGO-Led Model of Integrated Harm Reduction and DAA Treatment for PWUDs	B Janikova, Spolecnost Podane Ruce, Czech Republic
PO4/21	Mental Health and Prevention Interventions targeting LGBTQ+ Asylum Seekers	J Farrell, Choices Support Center, the Netherlands